Enfiera 500mg injection | Rituximab | MHP - PowerPoint PPT Presentation

About This Presentation
Title:

Enfiera 500mg injection | Rituximab | MHP

Description:

Enfiera 500mg is an anticancer medicine which prevents the growth and spread of cancer cells in the body. – PowerPoint PPT presentation

Number of Views:25

less

Transcript and Presenter's Notes

Title: Enfiera 500mg injection | Rituximab | MHP


1
Enfiera 500mg injection Rituximab MHP
  • MILLION HEALTH PHARMACEUTICALS

2
DESCRIPTION
  • Enfiera 500mg is an anticancer medicine which
    prevents the growth and spread of cancer cells in
    the body.
  •  Enfiera 500mg injection also indicated for the
    treatment of Non- Hodgkins lymphoma or chronic
    lymphocytic and with combination with another
    anticancer drugs like methotrexate is used for
    rheumatoid arthritis symptoms in adult treatment. 

3
INDICATION
  • Enfiera 500mg and hyaluronidase human injection
    are given alone or combination with other drugs
    to treat certain types of non-Hodgkin's lymphoma
    and chronic lymphocytic leukemia (cancer start in
    WBC).
  • Enfiera 500mg injection is also used with
    methotrexate (Otrexup, Rasuvo, Xatmep, others)
    for the treatment rheumatoid arthritis symptoms
    in adults that have been already treated with
    some type of regimen known as tumor necrosis
    factor (TNF) inhibitor. 

4
INDICATION
  • NON HODGKINS LYMPHOMA
  • CHRONIC LYMPHOCYTIC LEUKEMIA

5
MECHANISM OF ACTION
  • Enfiera 500mg injection is a type of class called
    as monoclonal antibody and which is a new type of
    "targeted" cancer treatment and an integral part
    of the body's immune system.
  • Enfiera 500mg works by linking to the CD20
    antigen on normal and malignant B-cells. Hence
    the body's essential immune security is initiated
    to attack and kill the marked B-cells

6
PRODUCT DETAILS
  • Brand Enfiera
  • Ingredients Rituximab 
  • Strength 500mg 
  • Manufactured Biochem Pharmaceuticals
    Industries
  • Package
  • 50ml in a 1vial

7
PHARMACOKINETICS
  • ABSORPTIONNot availableDISTRIBUTIONvolume
    of distribution is 3.1 LMETABOLISMEnfiera
    500mg injection metabolized by human antimurine
    antibody production.EXCRETIONnot
    availableThe half-life of NHL is 22 days and for
    RA is 18.0 days, GPA and microscopic polyangiitis
    is 23 days

8
DOSAGE MANAGEMENT
  • Enfiera 500mg is recommended to administer only
    through intravenous infusion not by IV push or
    bolus.
  • ADMINISTRTION
  • Take an Enfiera 100mg amount and diluted to final
    concentration of 1 mg/ml up to 4 mg/ml as
    infusion (containing either 0.9 Nacl or 5
    dextrose in water). Invert gently the bag and mix
    the solution. Dispose unused drug left in vial.

9
PRECAUTIONS
  • Allergic condition against Enfiera 500mg
    injection or any other medication informs your
    doctor.
  • Avoid use of Enfiera 500mg injection if you are
    pregnant. It will harm the baby unborn, while
    using Enfiera 100mg use correct birth control to
    prevent pregnancy and for at least 2 weeks after
    your treatment ends.
  • It is unknown whether Enfiera 500mg passes into
    breast milk, avoid breast-feed while on Enfiera
    500mg treatment.

10
SIDE EFFECTS
  • Common effectsfever and chills (flu like
    symptoms)
  • Less common side effects
  • Weakness
  • nausea
  • headache
  • cough
  • dyspnea
  • pharyngitis

11
DRUG INTERACTION
  • Enfiera 500mg drug interaction has limited data
    is available at present.Combination with
    fludarabine or cyclophosphamide has no effects in
    pharmacokinetics in CLL patients.Combination
    with methotrexate had no effects in
    pharmacokinetics.

12
CONTRAINDICATIONS
  • Hypersensitivity or murine proteins.Active
    severe infections in rheumatoid
    arthritisUncontrolled cardiac disease.

13
PREGNANCY
  • Category C animal studies reproduction shown an
    adverse effect on the fetus.
  • The drug has no enough and well controlled
    studies in humans, using in pregnant women
    benefits by warrant use of the drug.

14
LACTATION
  • Enfiera 500mg injection excreted into human milk
    is unknown. Due to the drug belongs to large
    protein molecule, no information is available.
    Women should not breast feed during Enfiera 500mg
    treatment and 12 months following last dose.

15
STORAGE 
  • Store at 20C 30C Use the drug before
    expiry date Protected from direct sunlight Do
    not freeze or shake. Keep away from the
    childrens Discard the unused drug by asking
    the advice from doctor or pharmacist.

16
MISSED DOSE
  • If a dose missed to take at the time then have it
    suddenly before next dose timing, if time reach
    for next dose, then skip missed dose and continue
    and continue the regular schedule. Do not have 2
    doses at a same time.

17
OVERDOSAGE
  • If the patients had high dose of Enfiera
    500mg then seek immediately to the emergency
    department or poison control help line. Please
    consult the doctor for further clarification.

18
CONTACT US
  • EMAILID millionhealthpharmaceuticals_at_gmail.com
  • PHONE NO 
  • 91-9940472902
  • WEBSITE URL https//millionpharma.com/enfiera-500
    mg.php

19
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com